Therapeutic effectiveness against mopc-315 plasmacytoma of low or high doses of the synthetic thymic hormone THF-γ2 in combination with an “immunomodulating” or a “non-immunomodulating” drug-Reference-Cited by-同舟云学术

Therapeutic effectiveness against mopc-315 plasmacytoma of low or high doses of the synthetic thymic hormone THF-γ2 in combination with an “immunomodulating” or a “non-immunomodulating” drug

Published:2007-07-05 Issue:1 Volume:48 Page:96-100
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Ophir R.,Pecht M.,Burstein Y.,Harshemesh H.,Ben-Efraim S.,Trainin N.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference20 articles.

1. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma growth;Ben-Efraim;Cancer Immunol. Immunother.,1983

2. In vitro selective effect of Melphalan on human T-cell populations;Ben-Efraim;Cancer Immunol. Immunother.,1985

3. Classification of anticancer chemotherapeutic drugs according to their immunopotentiating activity;Ben-Efraim;Anticancer Res.,1986a

4. The difference between 5-fluorouracil and melphalan in their ability to promote anti-tumor immune response against MOPC-315 plasmacytoma;Ben-Efraim;Cancer Immunol. Immunother.,1986b

5. Tumoricidal and immunomodulatory activities of drugs and implications for therapy of mice bearing a late-stage MOPC-315 plasmacytoma;Berko;Int. J. Immunopharmacol.,1988

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thymic Humoral Factor-γ2 (Thf-γ2) Immunotherapy Reduces the Metastatic Load and Restores Immunocompetence in 3LL Tumor-Bearing Mice Receiving Anticancer Chemotherapy;Immunopharmacology and Immunotoxicology;1996-01

2. Effect of the synthetic regulatory peptide thymohexin on the production of various classes of immunoglobulins;Bulletin of Experimental Biology and Medicine;1994-10